Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.

Juergen Wolf,T. Overbeck,Ji Youn Han,Maximilian Hochmair,Filippo De Marinis,Kadoaki Ohashi,Egbert F. Smit,Danielle Power,Edward B. Garon,Harry J.M. Groen,Daniel Shao-Weng Tan,Maeve Waldron-Lynch,Sylvie Le Mouhaër,Ngozi Nwana,Monica Giovannini,Rebecca S. Heist

Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.

2020

Juergen Wolf
T. Overbeck
Ji Youn Han
Maximilian Hochmair
Filippo De Marinis
Kadoaki Ohashi
Egbert F. Smit
Danielle Power
Edward B. Garon
Harry J.M. Groen
Daniel Shao-Weng Tan
Maeve Waldron-Lynch
Sylvie Le Mouhaër
Ngozi Nwana
Monica Giovannini
Rebecca S. Heist

9509Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatmen...

Keywords:

Oncology
in patient
Capmatinib
Pathology
Medicine
Internal medicine
non-small cell lung cancer (NSCLC)
Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations